Lack of Evidence of Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure and Reduced Ejection Fraction Discharged on Spironolactone

Authors

P Lam
D Dooley
C Inampudi
C Arundel
G Fonarow
Wilbert S. Aronow, New York Medical CollegeFollow
A Ahmed
A Ahmed

Journal Title

International Journal of Cardiology

First Page

462

Last Page

466

Document Type

Article

Publication Date

January 2017

Department

Medicine

Abstract

BACKGROUND: Therapy with evidence-based heart failure (HF) medications has been shown to be associated with lower risk of 30-day all-cause readmission in patients with HF and reduced ejection fraction (HFrEF). METHODS: We examined the association of aldosterone antagonist use with 30-day all-cause readmission in this population. Of the 2443 Medicare beneficiaries with HF and left ventricular EF

Comments

Please see the work itself for the complete list of authors.

Recommended Citation

Lam, P., Dooley, D., Inampudi, C., Arundel, C., Fonarow, G., Aronow, W. S., Ahmed, A., & Ahmed, A. (2017). Lack of Evidence of Lower 30-Day All-Cause Readmission in Medicare Beneficiaries with Heart Failure and Reduced Ejection Fraction Discharged on Spironolactone. International Journal of Cardiology, 227, 462-466. https://doi.org/10.1016/j.ijcard.2016.11.006